Holiday Reading | Novo-Nordisk A/S Halved: Why is it Difficult for Pharmaceutical Stocks to Achieve High Valuations?
The increase and performance of China Meheco Group stocks this year is still ranked relatively high among All Sectors. The logic of gaining incremental growth through international expansion is gradually being realized, as Chinese companies' products are becoming increasingly popular. Overseas leading MNCs also tend to come to China to discover good early-stage Assets, and many leading companies have gradually crossed the profitability breakeven point. The entire Industry is still in a prosperous phase.
Hualan Biological Engineering, Inc.: Q1 revenue and net profit both increased, with last year's plasma collection reaching a historic high | Interpretations
① In Q1, the batch release volume of Hualan Biological Engineering, Inc.'s core blood products remains among the industry's top, and last year the company set a record high in plasma collection; ② In the vaccine business, due to seasonal factors, sales of Hualan's flu vaccine have not yet achieved large-scale growth, resulting in revenue pressure; ③ Since last year, the competition among domestic plasma stations has intensified.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Express News | DeepSeek-R2 will be released on March 17, and there has been no official response yet.
Total investment exceeds 19 billion! The leading company in the Shanghai Chlor-alkali Chemical Industry in Inner Mongolia signs a large L for the integrated green Energy project | After-hours announcement summary.
Zhejiang Crystal-optech: plans to acquire 95.6% of Aicos's shares for 0.3235 billion Cash / Money Market.
The amount involved exceeds 0.5 billion yuan and the equity transfer dispute of China Meheco Group is still ongoing | Quick read of the announcement.
① China Meheco Group has appealed to the court regarding the acquisition of the remaining 30% equity in Jinlun Pharmaceutical (now named Hebei Tongyong) held by Wang Yibing; ② The amount involved in this lawsuit reaches 0.51 billion yuan.